SUSD2-Based MSC Sorting for Robust Cell Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The inconsistent outcomes of mesenchymal stem cell (MSC) therapies are largely due to variations in MSC quality among donors, with aged or unhealthy donor MSCs showing reduced proliferation and differentiation capabilities. Additionally, MSC expansion through cell culture exacerbates aging issues.

Innovation Solution

The method involves cell sorting to select MSCs based on the lack of SUSD2 expression on their cell surface, thereby identifying a robust MSC subpopulation with reduced aging profiles. This process can be enhanced by using detectably labeled specific binding agents for SUSD2 and EPCAM, followed by sorting using techniques like magnetic or fluorescence-activated cell sorting.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If MSC expansion is performed through cell culture, then the quantity of MSCs is increased, but the aging profile of MSCs is aggravated

Engineering Contradiction:

Improvequantity of MSCsVSAvoidaging profile

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent extracts and removes aged MSCs from the cell population by sorting for SUSD2 expression. Aged MSCs are separated from the culture, allowing only robust, younger MSCs to remain for therapeutic use, thus resolving the contradiction between increasing quantity through culture and maintaining young phenotype.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the selection parameter from traditional culture-based expansion to surface marker expression (SUSD2) for identification and sorting. This parameter change enables direct selection of robust MSCs based on their aging status rather than relying on passage number, solving the contradiction between quantity and aging profile.

Inventive Principle:

Principle #35Parameter changes

2Quantity of substance

If MSCs are used from aged or unhealthy donors, then the availability of MSCs is improved, but the proliferative and differentiation capacity is reduced

Engineering Contradiction:

Improveavailability of MSCsVSAvoidproliferative and differentiation capacity

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent extracts and removes MSCs with poor proliferative and differentiation capacity (from aged/unhealthy donors) by sorting for SUSD2 expression. Only robust MSCs with young phenotype are retained, thus improving both availability and functional capacity simultaneously.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses SUSD2 expression as an intermediary marker to indirectly assess and select for robust MSCs. This intermediary parameter allows identification and selection of functionally competent cells without directly measuring proliferation or differentiation capacity, resolving the contradiction between availability and functional reliability.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If cell sorting is performed to select robust MSCs, then the quality and robustness of MSCs is improved, but the complexity of the process is increased

Engineering Contradiction:

Improvequality and robustness of MSCsVSAvoidcomplexity of sorting process

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses detectable labels (fluorescent or magnetic) conjugated to anti-SUSD2 antibodies to make aging status visually detectable. This color/signal change enables simple flow cytometry or magnetic sorting, improving quality while keeping the process accessible and not overly complex.

Inventive Principle:

Principle #32Color changes

Solution Approach 2:

The patent introduces SUSD2 expression as an intermediary marker that mediates between the complex biological state of cellular aging and the sorting process. This intermediary allows robust MSCs to be identified and separated using standard flow cytometry or magnetic sorting techniques, improving quality without requiring overly complex devices.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for the isolation of MSCs with improved robustness, proliferative capacity, and ability to differentiate into appropriate tissues, thereby enhancing the consistency and effectiveness of MSC therapies. The selected MSCs exhibit a more youthful phenotype, reducing cellular aging and improving therapeutic outcomes.

Implementation Method 1

the cells are contacted with a detectably labeled specific binding agent for SUSD2 prior to being sorted. In particular embodiments the specific binding agent is an antibody or antigen-binding fragment thereof that specifically binds SUSD2

Methodology Applied

Scientific EffectSpecific binding:

Implementation Method 2

the detectable label is a magnetic label and the cells are sorted by magnetic cell sorting

Methodology Applied

Scientific EffectMagnetic sorting:

Implementation Method 3

in alternative methods the detectable label is a fluorescent label and the cells are sorted by fluorescence-activated cell sorting methods (FACS)

Methodology Applied

Scientific EffectFluorescence-activated cell sorting: Fluorescence

Data Source

PatentUS20250076296A1Reagents and methods for preparing robust mesenchymal stromal cells for therapy

Publication Date: 2025.03.06 WISCONSIN ALUMNI RES FOUND

AI summary

The present disclosure provides reagents and methods for selecting MSCs having advantageous properties for therapeutic applications, particularly those related to cellular aging and producing MSCs of appropriate and sufficient robustness.